Young Consumers Show Deep Skepticism of GLP-1 Drugs While Embracing Wearables
A study of 1,400 Gen Next consumers reveals fragmented trust in health trends, from pharmaceutical skepticism to Apple Watch loyalty
Cafeteria, a consumer intelligence platform, has released findings from 1,400 young consumers discussing health and wellness spending habits, trust patterns, and product perception. The research drew from 240 hours of in-app private text and voice notes collected through the platform.
The data reveals pronounced skepticism toward GLP-1 medications among Gen Next consumers, even as these drugs have gained significant mainstream adoption. Simultaneously, the cohort demonstrates strong loyalty to established wearable devices, particularly Apple Watch and Oura. This split reflects a broader pattern: young consumers exhibit selective trust, embracing products they perceive as proven while remaining suspicious of newer pharmaceutical interventions.
Beyond pharmaceuticals, the study identifies consumer concerns about wellness products that "start to feel like a scam." This language suggests fatigue with the broader wellness industry and its proliferation of unproven claims. The research captures which brands and product categories have successfully maintained credibility with this demographic and which have lost it through perceived overselling or lack of substantive results.
The 240 hours of collected notes represent granular consumer sentiment difficult to capture through traditional surveys. By aggregating voice and text data, Cafeteria created a detailed map of how Gen Next evaluates health spending decisions—what they prioritize, which influencers or sources they trust, and where skepticism holds strongest. The scope of the sample suggests meaningful patterns rather than isolated opinions.
The findings carry implications for companies across health and wellness sectors. Pharmaceutical manufacturers face an authenticity challenge with younger consumers despite clinical efficacy. Meanwhile, device manufacturers who have built consumer trust appear positioned to expand their role in health monitoring. The data suggests Gen Next consumers distinguish sharply between products with transparent efficacy claims and those perceived as marketing-driven.